In today's trade, shares of SBI Life, Trent, Tata Investment, HCL Tech, Suzlon Energy among others will be in focus due to various news dev...

Aurobindo Pharma has announced an Rs 800 crore share buyback via the tender route, offering Rs 1,475 per share. The buyback opens April 23 ...

Aurobindo Pharma has announced an ₹800-crore buyback at ₹1,475 per share, with April 17, 2026 set as the record date—meaning investors must...

Four companies—Wipro, Cyient, Windlas Biotech, and Aurobindo Pharma—are set to announce or act on share buybacks this month, with Aurobindo...

Aurobindo Pharma is launching its first share buyback in two years, offering to repurchase over 54 lakh shares at Rs 1,475 each. This tende...

NCERT has issued an apology for a chapter in its Class 8 Social Science textbook. The organization has withdrawn the entire book titled 'Ex...

Dr Reddy's has denied the workforce reduction claims. "We categorically deny the claim of a 25% workforce cost reduction and the other clai...

Piramal Enterprises announced that the administrative committee of its board of directors will meet on December 20 to consider public issua...

Aurobindo Pharma announced on Thursday that its board has approved a buyback of 51.37 lakh shares at Rs 1,460 per share, marking a 6.4% pre...

Stellaris Ventures Partners, one of the early stage investors in Mamaearth parent Honasa Consumer, sold partial stake in the company throug...

Business tycoon Gautam Adani and Adani Group are expected to bid for the Ahmedabad franchise and they are considered to be favorites as the...

There are 22 companies which have picked up tender document worth Rs 10 lakh but with base price for new teams pegged at Rs 2000 crore, the...

"His resignation was considered and accepted by the board of directors in its meeting today. N Govindarajan will be relieved from the servi...

The approval further strengthens the company's HIV product basket in South Africa, which has the potential to improve the lives of millions...

Aurobindo's latest bid comes on the heels of last month’s shot at Israeli drug maker Teva's UK product portfolio, where it was outbid by ri...

The deal, said to be valued up to $1.5 billion, has seen the Hyderabadbased Aurobindo Pharma emerge as one of the front runners in the init...

Aurobindo expects to acquire personnel, commercial infrastructure, products, marketing authorisations and dossier licence rights in seven E...